MDEV - ETF AI Analysis
Top Page
First Trust Indxx Medical Devices ETF (MDEV)
Rating:64Neutral
Price Target:―
Positive Factors
Strong Performer Among Top Holdings
One of the largest positions has delivered very strong gains this year, helping support the fund’s overall results.
Global Medical Devices Focus
The ETF invests in medical device companies across several countries, giving investors targeted exposure to a specialized global healthcare niche.
Recent Short-Term Rebound
The fund has shown a solid bounce over the past month, suggesting some recovery momentum after earlier weakness.
Negative Factors
High Expense Ratio
The fund’s management fee is relatively high for an ETF, which can eat into long-term returns.
Recent Overall Underperformance
Year-to-date and recent multi-month performance have been weak, indicating the ETF has struggled in the current market environment.
Concentrated in One Sector
With most assets in health care and medical devices, the fund is heavily exposed to sector-specific risks and regulatory changes.
MDEV vs. SPDR S&P 500 ETF (SPY)
AUM1.86M
RegionGlobal
Expense Ratio0.70%
Beta0.73
IssuerFirst Trust
Inception DateJun 22, 2021
Dividend YieldN/A
Asset ClassEquity
Index TrackedIndxx Global Medical Equipment Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume949
30 Day Avg. Volume327
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
22.96Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering50
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MDEV Summary
The First Trust Indxx Medical Devices ETF (MDEV) follows the Indxx Global Medical Equipment Index and focuses on companies that make medical devices used in diagnosis, surgery, and patient care. It holds a global mix of health care equipment makers, including well-known names like Baxter International and Align Technology. Investors might consider MDEV if they want targeted exposure to the growth of medical technology and an aging population that is likely to need more health care. A key risk is that it is heavily concentrated in the medical devices sector, so its price can rise or fall sharply with that industry.
How much will it cost me?The First Trust Indxx Medical Devices ETF (MDEV) has an expense ratio of 0.7%, which means you’ll pay $7 per year for every $1,000 invested. This is higher than average because it is actively managed to focus on a specialized niche in the health care sector, requiring more research and management effort. While it costs more, it provides targeted exposure to innovative medical device companies.
What would affect this ETF?The First Trust Indxx Medical Devices ETF (MDEV) could benefit from positive trends such as aging populations, increasing global health care spending, and ongoing advancements in medical technology, which drive demand for innovative medical devices. However, potential risks include regulatory changes, rising interest rates that could impact borrowing costs for companies in the sector, and global economic slowdowns that may reduce health care budgets. As a globally focused ETF with exposure to leading medical device companies like Sartorius Stedim Biotech and HOYA, its performance will also depend on international market conditions and currency fluctuations.
MDEV Top 10 Holdings
MDEV is a pure play on global medical devices, and its story is one of selective strength mixed with a few problem children. Growth names like Align Tech and West Pharmaceutical are doing much of the heavy lifting, with rising momentum and upbeat earnings helping support the fund. Teleflex also looks steady to rising as it reshapes its portfolio. On the flip side, Carl Zeiss Meditec and Baxter are lagging, with weaker trends that act like a brake on returns. Overall, it’s a globally diversified but tightly focused bet on health care equipment innovation.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| West Pharmaceutical Services | 2.46% | $45.03K | $22.08B | 46.63% | 68 Neutral | |
| Shanghai MicroPort MedBot (Group) Co., Ltd. Class H | 2.34% | $42.92K | HK$30.06B | 53.82% | 38 Underperform | |
| ― | 2.25% | $41.30K | ― | ― | ― | |
| Edwards Lifesciences | 2.25% | $41.25K | $47.97B | 10.87% | 79 Outperform | |
| Carl Zeiss Meditec | 2.19% | $40.16K | €2.35B | -55.28% | 60 Neutral | |
| WuXi AppTec Co., Ltd. Class H | 2.19% | $40.08K | HK$371.37B | 126.07% | 69 Neutral | |
| Olympus | 2.15% | $39.40K | $11.07B | -17.80% | 68 Neutral | |
| Teleflex | 2.13% | $39.08K | $5.45B | 0.94% | 68 Neutral | |
| Straumann Holding AG | 2.13% | $39.02K | CHF13.98B | -14.18% | 72 Outperform | |
| Intuitive Surgical | 2.12% | $38.90K | $159.99B | -15.74% | 78 Outperform |
MDEV Technical Analysis
Negative
―
Price Trends
19.28
Negative
20.17
Negative
20.34
Negative
Market Momentum
-0.28
Positive
41.97
Neutral
31.73
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MDEV, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 19.14, equal to the 50-day MA of 19.28, and equal to the 200-day MA of 20.34, indicating a bearish trend. The MACD of -0.28 indicates Positive momentum. The RSI at 41.97 is Neutral, neither overbought nor oversold. The STOCH value of 31.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MDEV.
MDEV Peer Comparison
Comparison Results
Performance Comparison
MDEV
First Trust Indxx Medical Devices ETF
18.54
-1.44
-7.21%
FMED
Fidelity Disruptive Medicine ETF
―
―
―
HTEC
ROBO Global Healthcare Technology and Innovation ETF
―
―
―
HRTS
Tema Cardiovascular and Metabolic ETF
―
―
―
OZEM
Roundhill GLP-1 & Weight Loss ETF
―
―
―
PSIL
AdvisorShares Psychedelics ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents